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AIDS Research at the 
HHH Cancer Center 
One of the distinguishing features of 
AIDS is a marked loss of a group of 
white blood cells called helper cells 
(cells that help or promote immune 
reactions). Since the immune system is 
exquisitely balanced between the pre-
sence of helper cells and suppressor 
j ^ ^ e l l s (cells that suppress or limit 
xnmune reactions), a decrease in 
helper-cell number or function can 
cause a loss of immune competence. 
The end result is that the body can't 
fight infection. 
At the Humphrey Center, what re-
searchers observed is that not only are 
helper cells destroyed by the HTLV-III 
virus, but the ability to replace cells also 
is impaired. Because of this diminished 
capacity for renewal, there must be 
mechanisms at work in addition to a 
virus killing off cells. Research carried 
out by Paul H . Black, M.D., John C. 
Beldekas, Ph.D. and Elinor H . Levy, 
Ph.D., is focused on exploring — and, it 
is hoped, eliminating — those potential 
other mechanisms through tests with 
in vitro T-cell assays. 
In vitro T-cell assays are a means by 
which to measure the ability of AIDS 
patients' blood cells to grow and form 
colonies while a variety of tests are 
performed on the cells in a test tube. 
The tests include administration of 
anti-viral drugs, investigation of the 
effect of viral proteins on non-infected 
cells, and exploration of the possibility 
•hat affected cells could be producing 
"impotent" cells. 
There are no clear answers yet, but 
if the range of possibilities can be nar-
rowed, that's progress in research. • 
I 
Michael E. Osband, M.D. 
M 
m 
The Fight Against Cancer Gets a Shot 
in the Arm: Adoptive Immunotherapy 
Immunotherapy starts with the hypo-
thesis that the immune system can tell 
that cancer cells aren't a normal part of 
a patient's body. This is because of 
substances called antigens that may be 
on the surface of these cancer cells. 
Michael E. Osband, M.D., a member 
of the Humphrey Center and medical 
director of the Laboratory for Cellular 
Immunology and Cancer Diagnosis, is 
using this hypothesis as a basis for 
further investigation into the possibility 
of a cancer treatment called adoptive 
immunotherapy. The results are prom-
ising. 
Dr. Osband and his BUSM colleagues 
Gennaro A. Carpinito, M.D., assistant 
professor, and Robert J. Krane, M.D., 
chairman of the Department of Urol-
ogy, began their investigation with a 
look at how the immune system re-
sponds to organ transplants. When a 
transplant is performed, the patient's 
immune system must be suppressed to 
prevent rejection of the new organ. "If 
the body rejects a transplant because 
the antigens on the cells of the donor 
organ are different from the patient's," 
Dr. Osband asks, "wouldn't it follow 
that the body might reject cancer cells 
for the same reason?" 
Because people continue to 
develop cancer and die from 
it, it's apparent that our 
immune systems, by them-
selves, do not reject 
abnormal cancer . ^ ^ ^ ^ \ ^ ^ 
cells. Dr. Osband 
and his col-
leagues 
continued on 
page 3. 
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The AIDS Epidemic: 
Report on a 
Frustrating Disease 
By Paul H. Black, M.D., John C. Beldekas, 
Ph.D. and Elinor M. Levy, PhD. 
Few diseases in the history of 
medicine have had the social and 
economic impact that we are currently 
experiencing with acquired immune 
deficiency syndrome (AIDS), a condi-
tion recognized only in the past few 
years. Moreover, the numerous un-
answered and only partially answered 
medical questions concerning this dis-
ease have engendered many fears and 
frustrations in the high-risk groups, 
among medical personnel and in the 
general population. 
AIDS has presented modern medi-
cine with one of its most difficult 
challenges. The slow but steady spread 
of the disease wi l l place an ever-
increasing proportion of the popula-
tion at risk unless effective interven-
tion and treatment can be found soon. 
The search for additional insight into 
causal factors, prevention, epidemiol-
ogy, pathogenesis and treatment is 
intensifying. 
Who is at risk? 
Approximately 75 precent of AIDS 
patients are homosexual or bisexual 
males, and about 15 percent are intra-
venous drug abusers. About 5 percent 
of AIDS patients are of Haitian descent, 
hemophiliacs who receive factor VI I I 
preparations, which are required for 
blood clotting, or patients who receive 
blood transfusions. Approximately 5 
percent of patients with AIDS are not 
known to belong to any of these risk 
groups. 
A syndrome sometimes seen in 
high-risk groups is AlDS-related com-
plex (ARC). It is characterized by 
fever, malaise, weight loss, appetite 
loss, swelling of the lymph glands and 
some immune suppression. Approx-
imately 10 to 15 percent of the people 
with this syndrome have developed 
full-blown cases of AIDS. 
Virus found, test developed 
Within the past two years, two 
groups of scientists — one in France 
and another in the U.S. at the National 
Cancer Institute — identified a virus 
COMMENTARY 
that seems to be the causal factor in 
AIDS. Tests have been developed to 
detect the presence of antibodies to 
this virus referred to as lympha-
denopathy-associated virus (LAV) by 
the French group and human T-cell 
lymphotropic virus I I I (HTLV-III) by 
the Americans. The test most frequent-
ly used is the enzyme-linked immuno-
sorbent assay (ELISA), which recently 
was approved for use by the Food and 
Drug Administration. 
Paul H. Black, M.D., is professor and chairman 
of the BUSM Department of Microbiology and a 
member of the Massachusetts Task Force on 
AIDS that was established by the governor. He 
is a former director of the Humphrey Cancer 
Center. Elinor M. Levy, Ph.D., an associate pro-
fessor, and John C. Beldekas, Ph.D., a research 
associate, are members of Black's department 
and are conducting AHDS-related research. 
Limitations of the ELISA test 
The current major clinical application 
of ELISA is to screen blood and blood 
products, thereby helping to minimize 
the risk of transfusion-associated AIDS. 
ELISA is not completely specific for 
the AIDS virus, however, and it may 
yield both false positive and false 
negative results. 
A positive test means only that a 
person has had contact with the virus 
and has developed antibodies to it. It 
does not mean that the person has 
AlDS-related complex or AIDS or that 
he or she wi l l eventually get these dis-
eases. It is not even certain that every 
person with a positive test harbors the 
infectious virus, although some symp-
tom-free people certainly do. 
The use of ELISA also presents com-
plex legal, social and ethical issues. 
These questions mostly arise from 
fears surrounding the confidentiality of 
the test results and a concern about 
whether names of people with positive 
results would be made available to 
employers or insurance companies 
who might use the information to 
deny jobs or insurance coverage. 
With the availability of ELISA and 
other screening tests, it has become 
apparent that some healthy people in 
the high-risk groups are antibody posi-
tive and may even harbor the virus. 
Although these people must be studied 
for longer periods of time, antibody 
and/or viral presence without the dis-
ease suggests that the virus alone is 
not sufficient to cause AIDS. This 
raises questions of whether, and what, 
co-factors may be necessary for the 
development of the disease. Much 
more has to be learned about these co-
factors and the role they play in the 
development of AIDS; this may well 
be the most important issue facing 
AIDS researchers. 
Contagiousness and treatment 
Data from patients with AIDS indi-
cate that the virus is not very infec-
tious. The disease appears to be spread 
only by intimate sexual contact, by 
sharing drug needles, or by blood 
products from infected individuals. 
The disease is not spread by casual 
contact, or in water or food, or by air 
or such contaminated objects as books, 
bedding, combs and clothing. So far it 
seems unlikely that the disease can be 
spread by kissing, since the amount of 
the virus is relatively low in saliva. 
It is important to note that there has 
been no documentation to date of 
cases in which the disease has been 
spread to health-care workers who 
have cared for AIDS patients. 
There is no effective treatment for 
AIDS at present. Many studies are 
now being carried out with drugs that 
inhibit enzymes within the virus that 
are necessary for replication. Many of 
these drugs, however, may lead to 
blood cell or kidney damage. Studies 
of these drugs wi l l continue and they .^..^ ^^  
wi l l be tested in patients with AlDS-
related complex. In these patients, the 
immune system has not been so 
irreparably damaged as it is in people 
continued on page 3. 
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A Day of Celebration 
Director Herbert Wotiz, Ph.D., (left) presents an award to Robert C. Gallo, M.D. 
Robert C. Gallo, M.D., who was pre-
sented with the 1985 Hubert H . 
Humphrey Cancer Research Center 
Award by Humphrey Center Director 
Herbert Wotiz, Ph.D., is renowned for 
his groundbreaking research efforts into 
the nature of viruses, especially those 
related to leukemia. He is well-known 
in the scientific community for his 
identification of the biological response 
modifier, interleukin 2, a molecule 
potentially able to alert the immune 
lystem to tumor cells and, thereby, 
useful in the treatment of cancer. 
As chief of the Laboratory of Tumor 
Cell Biology, Developmental Thera-
peutics program, of the National Can-
cer Institute in Bethesda, Md., Gallo 
continues to contribute to the under-
standing of the devastating acquired 
immune deficiency syndrome (AIDS). 
"So far we don't have the vaccine or 
right treatment for this devastating dis-
ease; I am hopeful that soon we wi l l 
have both. If so then this award may 
become appropriate in bearing the 
name of Hubert Humphrey, who gave 
so much to biomedical science, and 
who knew so much about courage and 
personal suffering in cancer. " • 
QUESTIONS. . . 
Answer to question on back panel. 
A. Smoking is the single most pre-
ventable cause of cancer today. If 
everyone were to stop smoking, nearly 
one-third of all cancer-related deaths 
could be prevented. Smoking is re-
sponsible for 83 percent of all lung 
cancer, the form of cancer most dif-
ficult to treat and cure — 85 percent of 
lung cancer patients die of the disease. 
Smoking is also a factor in cancers of 
the mouth, throat, larynx and pancreas. 
Cancers related to smoking claim 
320,000 lives a year — largely pre-
ventable deaths. 
Q . Is diet related to cancer? 
A. The present evidence linking can-
cer with diet is based upon laboratory 
experiments and observation of human 
populations. A high fat diet, including 
both unsaturated and saturated fats, 
may play an important role in cancers 
of the breast, colon and uterus. In fact, 
recent studies have shown that obese 
people have significantly higher death 
rates from these three types of cancer. 
continued on page 4. 
AIDS EPIDEMIC 
continued from page 2. 
with AIDS. (Please see page 1 story about 
some AlDS-related research being conducted 
at the Humphrey Center.) 
Incidence on the increase 
The incidence of the disease is 
increasing and it appears to be spread-
ing. In the U.S., the disease occurs pre-
dominantly among men. However, 
there is epidemiological evidence in 
this country that the disease can be 
transmitted heterosexually. The dis-
ease recently has been documented in 
prostitutes in San Francisco, New York 
City and Boston. Sexual contact with 
prostitutes previously exposed to the 
virus may explain some of the cases 
classified as being in the "no-known-
risk" category. 
Approximately 80 to 85 percent of 
patients with AIDS wi l l have died of 
their disease within two years of diag-
/^'^nosis. A great challenge to the medical 
and research community today is to 
understand the nature and pathogene-
sis of AIDS. Only through such under-
standing can we hope to bring about 
effective prevention and therapy. • 
IMMUNOTHERAPY 
continued from page 1. 
developed a technique called in vitro 
immunization. Some of a patient's 
white blood cells, the kind called 
lymphocytes, are put into a test tube, 
incubated with some of the patient's 
cancer cells, then put back into the 
patient. These sensitized or immunized 
cells can attack the cancer, similar to 
the way in which a polio vaccine, for 
example, stimulates the immune sys-
tem to fight the polio virus. 
To address the second possibility — 
that the immune response is too weak 
or has been turned off too early — the 
question was raised whether any drugs 
were available that might, in effect, 
amplify the efforts of the body's 
immune system. The answer was yes. 
And the drug was cimetidine, already 
widely-used for treating ulcers. Cimeti-
dine seems in certain cases to increase 
an immune response by turning off 
the suppressor lymphocytes (the cells 
that regulate the immune system) and 
so unleashes the immune response. 
Dr. Osband simply took a known, safe 
drug and used it in this new application. 
In addressing both possibilities. Dr. 
Osband and his colleagues developed 
a method of treating cancer: adoptive 
immunotherapy. 
Early data on the anti-cancer proper-
ties of cimetidine in mice were pub-
lished by Dr. Osband and his colleagues 
in 1981. Then 20 terminally i l l patients 
with kidney cancer were treated in 
what is called a Phase 1 study, to deter-
mine if this treatment was safe. Each 
patient received three infusions of 
their in vitro immunized lymphocytes 
and took cimetidine orally each day. 
There was no toxicity. Dr. Osband 
notes, and the tumors shrank in nearly 
50 percent of the patients. The results 
justified expanded clinical trials, and 
after some additional studies on mice, 
a study of 60 more terminal cancer 
patients got under way in February1986. 
The study focuses on cancers of the 
kidney, lung, pancreas, colon and skin. 
While it's too soon to know whether 
adoptive immunotherapy wi l l help all 
cancer patients, the fact that the treat-
ment continues to be tested in clinical 
trials — with some positive results — 
is hopeful. • 
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QUESTIONS... 
continued from page 3. 
Consuming fewer fatty foods — such 
as butter, margarine, vegetable oil, lard, 
salt pork, shortening, olives and non-
dairy creamer — is believed to help 
reduce your risk of developing cancer. 
Further, many cancers common to 
Western nations — such as cancers of 
the prostate, breast, colon and rectum 
— are rare or nonexistent among rural 
Africans, whose diets are much higher 
in fiber than the American diet. Eating 
more high-fiber foods is also believed 
to help reduce your risk of developing 
cancer. Fiber is the non-digestible car-
bohydrate found in whole grains, 
beans, fruit and vegetables.• 
C A N C E R N O T E S 
CANCER NOTE: More than 400,000 
new cases of skin cancer are reported 
every year, making it the most com-
mon form of human cancer. Fortunate-
ly, it is one of the most curable forms 
of cancer when discovered early. Most 
skin cancer can be prevented since 
over exposure to the sun is the leading 
cause. Wearing protective clothing, 
using strong sunscreens and staying 
out of strong sunlight are sensible pre-
ventive measures, especially for fair-
skinned people with red or blond hair 
— characteristics of people most prone 
to develop skin cancer. 
CANCER NOTE: Cigarettes are not the 
only form of tobacco known to cause 
cancer. Cigars, pipes and chewing 
tobacco have been implicated in cancers 
of the mouth and throat. Even "second-
hand" smoke may cause disease. 
The Humphrey Cancer Center News 
is published by the Hubert H. Hum-
phrey Cancer Research Center of 
Boston University School of Medicine. 
John I . Sandson, M.D., Dean of the 
School of Medicine; Director, Herbert 
H. Wotiz, Ph.D.; Deputy Director, Isaac 
M. Taylor, M.D.; Editor, William J. Free-
man. "Cancer Notes" information is 
provided courtesy of the American 
Cancer Society. 
What is the single most 
preventable cause of cancer? 
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